Fibrosarcoma - WEHI164 Cells

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Fibrosarcoma is a malignant mesenchymal tumor derived from fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in the storiform pattern. Fibrosarcoma mainly arise in people between the ages of 25-79. It originates in fibrous tissues surrounding the bone and invades long or flat bones such as the femur, tibia, and mandible. For high-grade fibrosarcoma, 5-year survival rates are as low as 30%. For low-grade fibrosarcoma, survival rates are around 50-75%.

The WEHI-164 cell line provides a mouse fibrosarcoma model.  It was derived from a BALB/c mouse and established from a fibrosarcoma induced by subcutaneous injections of 3-methylchloanthrene. In vivo, these tumors grow slowly for the first two weeks. Control animals stay on study for 30-35 days prior to reaching euthanasia criteria. This results in a model which can facilitate up to a four-week dosing window for test agents to elicit their anti-tumor activity.

Growth kinetics validation.  2 x 10WEHI164 mouse fibrosarcoma cells (derived from BALB/c mice) were subcutaneously injected into the rear flank of BALB/c mice. Tumor growth volume was monitored approximately twice / week using calipers (Data are mean± SEM; n=20).

The mouse fibrosarcoma model accommodates a variety of study designs.   In addition to tumor volume a variety of additional physiological parameters and biomarkers, such as cytokine levels,  can be incorporated into the study design.  Study durations can range from 3 to 6 weeks.